BR112013014583A2 - composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila - Google Patents

composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila

Info

Publication number
BR112013014583A2
BR112013014583A2 BR112013014583A BR112013014583A BR112013014583A2 BR 112013014583 A2 BR112013014583 A2 BR 112013014583A2 BR 112013014583 A BR112013014583 A BR 112013014583A BR 112013014583 A BR112013014583 A BR 112013014583A BR 112013014583 A2 BR112013014583 A2 BR 112013014583A2
Authority
BR
Brazil
Prior art keywords
treating
methanesulfonylpropionitrile
preparing
methods
pharmaceutical composition
Prior art date
Application number
BR112013014583A
Other languages
English (en)
Portuguese (pt)
Inventor
Joseph P St Laurent
Original Assignee
Olatec Ind Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Ind Llc filed Critical Olatec Ind Llc
Publication of BR112013014583A2 publication Critical patent/BR112013014583A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/02—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C255/03—Mononitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112013014583A 2010-12-15 2011-12-13 composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila BR112013014583A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42348510P 2010-12-15 2010-12-15
PCT/US2011/064590 WO2012082718A2 (en) 2010-12-15 2011-12-13 3-methanesulfonylpropionitrile for treating inflammation and pain

Publications (1)

Publication Number Publication Date
BR112013014583A2 true BR112013014583A2 (pt) 2016-09-20

Family

ID=46235178

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013014583A BR112013014583A2 (pt) 2010-12-15 2011-12-13 composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila

Country Status (11)

Country Link
US (8) US8476316B2 (cg-RX-API-DMAC10.html)
EP (1) EP2651407B1 (cg-RX-API-DMAC10.html)
JP (1) JP5932830B2 (cg-RX-API-DMAC10.html)
KR (1) KR101849813B1 (cg-RX-API-DMAC10.html)
CN (1) CN103260613B (cg-RX-API-DMAC10.html)
AU (1) AU2011344030B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013014583A2 (cg-RX-API-DMAC10.html)
CA (1) CA2820625C (cg-RX-API-DMAC10.html)
MX (1) MX2013006708A (cg-RX-API-DMAC10.html)
TW (1) TWI522338B (cg-RX-API-DMAC10.html)
WO (1) WO2012082718A2 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102002664B1 (ko) 2012-02-27 2019-07-23 오라텍 세라퓨틱스 엘엘씨 3-메틸술포닐프로피오니트릴의 제조 방법
AU2013271778B2 (en) * 2012-06-05 2018-03-01 Olatec Therapeutics Llc Pharmaceutical composition for treating inflammation and pain
US9481644B2 (en) 2012-06-05 2016-11-01 Olatec Therapeutics Llc Pharmaceutical composition comprising omega-(arylsulfonyl)alkylnitrile
JP6185575B2 (ja) 2012-06-05 2017-08-23 オラテック セラピューティクス リミティド ライアビリティ カンパニー 皮膚炎症性疾患の治療方法
CA2875053C (en) * 2012-06-05 2020-07-14 Olatec Industries Llc Pharmaceutical composition for treating inflammation and pain
MX368641B (es) 2012-06-11 2019-10-09 Olatec Ind Llc Compuestos para el tratamiento de inflamación y dolor.
US9114122B2 (en) 2012-06-14 2015-08-25 Olatec Industries Llc Compounds for treating inflammation and pain
WO2013188314A1 (en) * 2012-06-14 2013-12-19 Olatec Industries Llc Compounds for treating inflammation and pain
SI3021873T1 (sl) * 2013-07-18 2018-12-31 Xalud Therapeutics, Inc. Sestavek za zdravljenje vnetne sklepne bolezni
WO2015026851A1 (en) 2013-08-20 2015-02-26 Olatec Industries Llc Pharmaceutical composition and use of diethyl (2-cyanoethyl)phosphonate
WO2015048328A1 (en) * 2013-09-26 2015-04-02 Olatec Industries Llc 3, 4-bis-benzylsulfonylbutanenitrile and its pharmaceutical use
US9440916B2 (en) 2013-09-26 2016-09-13 Olatec Therapeutics Llc 3, 4-bis-benzylsulfonylbutyronitrile and its pharmaceutical use
WO2015050878A1 (en) * 2013-10-01 2015-04-09 Olatec Industries Llc Pharmaceutical use of 3-benzylsulfonylpropionitrile
US9999610B2 (en) 2013-10-01 2018-06-19 Olatec Therapeutics Llc Pharmaceutical use of 3-benzylsulfonylpropionitrile
JP6426746B2 (ja) * 2013-10-07 2018-11-21 オラテック セラピューティクス リミティド ライアビリティ カンパニー 4−メチルスルホニル−2−ブテンニトリル及びその医薬上の使用
US9522878B2 (en) 2013-10-07 2016-12-20 Olatec Therapeutics Llc 4-methylsulfonyl-2-butenenitrile and its pharmaceutical use
WO2015081188A1 (en) * 2013-11-27 2015-06-04 Olatec Industries Llc Pharmaceutical composition comprising omega-(arylsulfonyl)alkylnitrile
US9949915B2 (en) 2016-06-10 2018-04-24 Clarity Cosmetics Inc. Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use
ES2970485T3 (es) * 2017-01-06 2024-05-29 Olatec Therapeutics Llc Composición farmacéutica para su uso en el tratamiento de enfermedades cardiovasculares
US10273203B2 (en) 2017-04-11 2019-04-30 Olatec Therapeutics Llc Deuterated 3-methanesulfonylpropionitrile
AU2018313164A1 (en) * 2017-08-11 2020-03-19 Olatec Therapeutics Llc Method for treating Schnitzler's syndrome
WO2019152627A1 (en) * 2018-01-31 2019-08-08 Olatec Therapeutics Llc Method for preventing or treating alzheimer's disease
JP7229565B2 (ja) * 2018-03-21 2023-02-28 オラテック セラピューティクス リミティド ライアビリティ カンパニー メラノーマを治療するための方法
JP7209981B2 (ja) * 2019-05-31 2023-01-23 日本たばこ産業株式会社 触覚刺激に対する幸福感の評価を補助するための方法及び触覚刺激に対する幸福感を評価するためのデータ取得方法
CA3141407A1 (en) * 2019-06-17 2020-12-24 Charles A. Dinarello Method for treating asthma
EP4045009A4 (en) 2019-10-14 2023-11-01 Olatec Therapeutics LLC METHOD FOR TREATING BREAST CANCER
WO2022226495A1 (en) * 2021-04-22 2022-10-27 Olatec Therapeutics Llc Method for treating spinal cord injury
CN118436631B (zh) * 2024-05-08 2025-07-01 中国人民解放军军事科学院军事医学研究院 达泮舒腈在预防和/或治疗急性放射性肺损伤中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3041155A1 (de) * 1980-10-31 1982-06-09 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2,3-dichlor-sulfonyl-acrylnitrilen
JPS58501722A (ja) 1981-10-16 1983-10-13 アボツト ラボラトリ−ズ 〔1↓−(2↓−ベンゾオキサゾリル)ヒドラジノ〕アルキルニトリル誘導体
US5175192A (en) * 1984-03-19 1992-12-29 The Rockefeller University Inhibitors of the advanced glycosylation of proteins and methods of use therefor
EP0355049A3 (en) 1988-08-18 1990-06-13 Zeneca Limited Heterocyclic compounds
US5348838A (en) 1991-07-31 1994-09-20 Kabushiki Kaisha Toshiba Photosensitive composition comprising alkali soluble binder and photoacid generator having sulfonyl group
KR100294084B1 (ko) 1998-06-02 2001-09-22 성재갑 비-스테로이드성소염진통제의경피흡수투여용조성물및이를포함하는경피흡수투여용제형
KR100288190B1 (ko) 1998-02-09 2001-04-16 김용규 피록시캄 함유 알콜성 하이드로겔 조성물
US6551615B1 (en) * 2001-10-18 2003-04-22 M/S. Strides Arcolab Limited Dexibuprofen-containing soft gelatin capsules and process for preparing the same
CN1528284A (zh) * 2003-10-06 2004-09-15 南昌弘益科技有限公司 蔊菜素滴丸及其制备方法
US7423064B2 (en) * 2004-09-24 2008-09-09 Olatec Industries, Llc Composition for treating bacterial, viral, fungal diseases, inflammation and pain
RU2642628C2 (ru) * 2006-02-16 2018-01-25 Анакор Фармасьютикалз, Инк. Бор-содержащие малые молекулы в качестве противовоспалительных средств
DE602006018367D1 (de) * 2006-03-20 2010-12-30 Olatec Ind Llc Zusammensetzung für die behandlung von bakteriellen erkrankungen, viruserkrankungen, pilzlichen erkrankungen, entzündungen und schmerzen
WO2008101060A1 (en) * 2007-02-14 2008-08-21 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
EP3246034A1 (en) * 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
JP5392261B2 (ja) 2008-08-12 2014-01-22 宇部興産株式会社 非水電解液及びそれを用いたリチウム電池
AU2010226794A1 (en) * 2009-03-18 2011-10-27 Olatec Industries Llc Compounds for treating inflammation and pain

Also Published As

Publication number Publication date
JP5932830B2 (ja) 2016-06-08
US8975297B2 (en) 2015-03-10
KR101849813B1 (ko) 2018-04-17
US10080735B2 (en) 2018-09-25
KR20140030122A (ko) 2014-03-11
US9492420B2 (en) 2016-11-15
US20170119725A1 (en) 2017-05-04
CA2820625A1 (en) 2012-06-21
US9770428B2 (en) 2017-09-26
JP2014503533A (ja) 2014-02-13
CN103260613A (zh) 2013-08-21
CA2820625C (en) 2019-04-02
EP2651407A4 (en) 2014-06-04
US20120157524A1 (en) 2012-06-21
US20140228433A1 (en) 2014-08-14
WO2012082718A2 (en) 2012-06-21
US8476316B2 (en) 2013-07-02
US20200237706A1 (en) 2020-07-30
US20190133988A1 (en) 2019-05-09
EP2651407A2 (en) 2013-10-23
US10500184B2 (en) 2019-12-10
AU2011344030B2 (en) 2017-03-30
US20130172410A1 (en) 2013-07-04
US11229620B2 (en) 2022-01-25
TW201305093A (zh) 2013-02-01
TWI522338B (zh) 2016-02-21
MX2013006708A (es) 2013-09-13
WO2012082718A3 (en) 2012-10-26
US8829046B2 (en) 2014-09-09
EP2651407B1 (en) 2016-12-21
CN103260613B (zh) 2015-01-14
AU2011344030A1 (en) 2013-07-11
US20150231106A1 (en) 2015-08-20
US20180125807A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
BRPI1007636A2 (pt) Composição farmacêutica, forma de dosagem, método para a preparação da composição farmacêutica, método de preparação da forma de dosagem e método de tratamento da dor
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
BR112012031836A2 (pt) combinação farmacêutica para o tratamento da dor
BR112013011968A2 (pt) composição farmacêutica, métodos de tratamento e usos da mesma
BR112013011874A2 (pt) compostos e métodos para tratar dor
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
PT2729151T (pt) Composição farmacêutica, métodos de tratamento e suas utilizações
BRPI1013640A2 (pt) composicao farmaceutica, metodos para o tratamento e usos dos mesmos
BR112014009686A2 (pt) composição analgésica inalável, pó seco e método para tratar dor
BR112015000441A2 (pt) imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22
BR112014023937A2 (pt) composição farmacêutica, agente farmacêutico de combinação e método de tratamento
BR112013009708A2 (pt) aparelhos, métodos e composições para tratamento endodôntico
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BR112012018943A8 (pt) medicamento e método para o tratamento e/ou prevenção de um câncer
PL2672966T3 (pl) Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania
PT2709604T (pt) Canabidivarina para utilização no tratamento de dor neuropática
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
IL235923B (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
BR112013004456A2 (pt) composição para tratamento de planta, e, método para o tratamento de plantas
BRPI1014528A2 (pt) compostos para tratamento de inflamação e dor
BR112015010501A2 (pt) composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada
BR112014015753A2 (pt) derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invenção
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
BR112013012062A2 (pt) derivados da piridazina, composições e métodos para tratar o comprometimento cognitivo
BR112015012877A2 (pt) composto de fórmula, composição farmacêutica, uso do composto e método para o tratamento do câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]